Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.
Coronary perforation is an uncommon but potentially life-threatening complication of percutaneous coronary intervention. The use of both atheroablative technologies for coronary intervention and adjunctive platelet glycoprotein blockade pharmacology may increase the incidence of or risk for life-threatening bleeding complications following the occurrence of coronary artery perforation. The interventional database for 6,214 percutaneous coronary interventions performed between January 1995 and June 1999 was analyzed. Hospital charts and cine angiograms for all patients identified in the database as having had coronary perforation were reviewed. Coronary perforation complicated 0.58% of all procedures and was more commonly observed in patients with a history of congestive heart failure and following use of atheroablative interventional technologies (2.8%). There was no association of abciximab therapy with either the incidence of or classification for coronary perforation. Adverse clinical outcomes (death, emergency surgical exploration) were related to the angiographic classification of perforation and were more frequently observed in patients who experienced a class 3 coronary perforation. These data suggest that specific clinical and procedural demographic factors are associated with the occurrence and severity of angiographic coronary perforation. An angiographic perforation class-specific algorithm for treatment of coronary perforation is proposed.
Dippel
E J
EJ
The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio 45219, USA.
Kereiakes
D J
DJ
Tramuta
D A
DA
Broderick
T M
TM
Shimshak
T M
TM
Roth
E M
EM
Hattemer
C R
CR
Runyon
J P
JP
Whang
D D
DD
Schneider
J F
JF
Abbottsmith
C W
CW
D000077284:Abciximab; D000368:Aged; D000465:Algorithms; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D016342:Angioplasty, Laser / Q000295:instrumentation*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D017225:Atherectomy, Coronary / Q000295:instrumentation*; D002932:Cineangiography; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D003331:Coronary Vessels / Q000293:injuries*; D005260:Female; D006335:Heart Injuries / Q000000981:diagnostic imaging / Q000628:therapy*; D006470:Hemorrhage / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000628:therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012189:Retrospective Studies; D012307:Risk Factors; D015607:Stents
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab